XENE Xenon Pharmaceuticals Inc.

15.5
-0.16  -1%
Previous Close 15.66
Open 15.78
Price To Book 6.01
Market Cap 401,142,759
Shares 25,880,178
Volume 498,410
Short Ratio
Av. Daily Volume 253,981
Stock charts supplied by TradingView

NewsSee all news

  1. Xenon Pharmaceuticals Announces Pricing of $60.0 Million Public Offering of Common Shares

    BURNABY, British Columbia, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of

  2. Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares

    BURNABY, British Columbia, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering

  3. Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update

    Xenon's Proprietary Programs Continue to Advance with Multiple Mid to Late Stage Clinical Trials Anticipated to be Underway in 2020 Xenon Eligible for Milestone Payments Based on the Advancement of Partnered

  4. Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting

    Overview of Clinical Stage XEN901 and Related Patient Survey to be Presented in the "Genetic Epilepsies – Updates in the Science and Diagnosis" Exhibit in Room 318-319 on Sunday, December 8th Pre-Clinical Work

  5. Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting

    Xenon's Epilepsy Programs Continue to Advance Including Ongoing XEN1101 Phase 2b Clinical Trial in Adult Focal Epilepsy and Plans for Anticipated Pediatric XEN496 Pivotal Phase 3 Clinical Trial in KCNQ2-DEE Patients

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data due 2H 2020.
XEN1101
Adult focal seizures
Phase 2 data released March 24, 2017 - endpoints not met.
XEN801
Acne
Phase 2b data released June 27, 2017. Endpoints not met.
TV-45070
Postherpetic neuralgia
Phase 2b trial did not meet endpoints - July 2015
TV-45070
Osteoarthritis
Phase 2 trial to be initiated in 2020.
XEN901
Pediatric epilepsy
Phase 3 trial to be initiated following IND filing 1Q 2020.
XEN496
Epilepsy
Phase 2 data due 2020.
XEN007
Childhood absence epilepsy

Latest News

  1. Xenon Pharmaceuticals Announces Pricing of $60.0 Million Public Offering of Common Shares

    BURNABY, British Columbia, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of

  2. Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares

    BURNABY, British Columbia, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering

  3. Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update

    Xenon's Proprietary Programs Continue to Advance with Multiple Mid to Late Stage Clinical Trials Anticipated to be Underway in 2020 Xenon Eligible for Milestone Payments Based on the Advancement of Partnered

  4. Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting

    Overview of Clinical Stage XEN901 and Related Patient Survey to be Presented in the "Genetic Epilepsies – Updates in the Science and Diagnosis" Exhibit in Room 318-319 on Sunday, December 8th Pre-Clinical Work

  5. Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting

    Xenon's Epilepsy Programs Continue to Advance Including Ongoing XEN1101 Phase 2b Clinical Trial in Adult Focal Epilepsy and Plans for Anticipated Pediatric XEN496 Pivotal Phase 3 Clinical Trial in KCNQ2-DEE Patients

  6. Xenon Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference

    BURNABY, British Columbia, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive

  7. Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update on License and Collaboration Agreement with Neurocrine Biosciences

    BURNABY, British Columbia, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, announced that it will host a conference call and live audio webcast at

  8. Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

    Neurocrine Biosciences Gains Rights to XEN901, a Clinical Stage Selective Nav1.6 Sodium Channel Inhibitor, Being Developed for the Treatment of Epilepsy Xenon Receives $50 Million Upfront and Up to $1.7 Billion in

  9. Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

    SAN DIEGO and BURNABY, British Columbia, Dec. 2, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) and Xenon Pharmaceuticals Inc. (NASDAQ:XENE) announced a license and collaboration agreement to develop

  10. Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

    BURNABY, British Columbia, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive

  11. Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Provide Corporate Update

    BURNABY, British Columbia, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2019 financial

  12. Xenon Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

    BURNABY, British Columbia, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive

  13. Xenon Announces Appointment of Shelley McCloskey as Senior Vice President, Human Resources

    BURNABY, British Columbia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical stage biopharmaceutical company, announced that Shelley McCloskey has joined the company's leadership